Glaxo Wellcome Relenza
Influenza A and B therapy gains additional indication April 27 for treatment of pediatric patients seven and older who have been symptomatic for no more than two days. Zanamivir was previously approved for treatment of patients over 12. The pediatric dose is the same as for adults, 10 mg twice daily
You may also be interested in...
Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011